Press Releases

Strengthens Leadership Team with Addition of Experienced Medical Device Executive   BOSTON, MA – July 15, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced the appointment of James Barry, Ph.D. as Chief Operating Officer. Barry, who has more than two decades of experience in the… Read More

100% procedural success rate achieved in first multi-specialty clinical experience BOSTON, MA – July 8, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it has concluded enrollment in its CARENET clinical trial. The multi-specialty (Interventional Cardiologists, Interventional Radiologists and Vascular Surgeons) trial is… Read More

BOSTON, MA – July 1, 2014 — InspireMD Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced that it has been selected to join the Russell MicrocapIndex, as of June 27, 2014. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in… Read More

BOSTON, MA – June 23, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to resume the manufacturing of its MGuard Prime EPS stent with a modified stent securement process . The Company also received approval to modify and re-deploy existing… Read More

BOSTON, MA – June 18, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the 9th Annual JMP Securities Healthcare Conference at the Westin New York Grand Central in New York. The Company will present at 11:00 a.m. ET on Wednesday, June… Read More

BOSTON, MA – May 7, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced financial and operating results for the quarter ended March 31, 2014.   Recent Events Initiated enrollment of patients into the CARENET (CARotid Embolic protection study using MicroNet™) for the CGuardTM… Read More

Study of 97 patients resulted in zero mortalities in STEMI patients as of 30-day follow up Results to be presented at EuroPCR meeting in Paris on Thursday, May 22nd at 4:50 p.m. CEST BOSTON, Ma – May 7, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection stents… Read More

BOSTON, MA – April 30, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has initiated a Voluntary Field Action (VFA) following recent reports  of MGuard Prime EPS stent dislodgements.  These reports have primarily occurred during the preparation of the MGuard Prime EPS, upon removal… Read More

BOSTON, MA – April 30, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will release its financial results for the quarter ended March 31, 2014 on Wednesday, May 7th.   The Company will host a conference call at 4:30 p.m. ET on Wednesday,… Read More

Proven Embolic Protection System Expands to Treat Carotid Artery Disease   BOSTON, MA – March 19, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems, today announced that it has successfully enrolled the first patient into the CARENET (CARotid Embolic protection study using microNET) multi-center European clinical trial for the… Read More